ClinicalTrials.gg
CompletedNCT07645638CODDIUpdated Jun 12, 2026

Virtual Reality Cognitive Stimulation for Alzheimer's

An interventional study of Virtual reality in Alzheimer Disease and Memory Disorders, sponsored by Universidad de Burgos. Completed at 1 site in Spain. Open to participants aged 60 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by Universidad de Burgos · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Jan 2025, registered May 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
60 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 279 studies in Alzheimer Disease with a site in Spain — 54 open to participants now, 80 under way, 24 of them phase 3. Alzheimer Disease · Spain.

Enrollment
222nd of 240
33 · median 258
Started
2025
with 20 others
No phase
66 of 279
17 open now
Registered
272nd of 279
by date

Among the 279 studies in Alzheimer Disease with a site in Spain, this one is the 222nd largest by enrollment of the 240 interventional ones that give a count, is one of 21 that started in 2025, is one of 66 with no phase, and was the 272nd registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

54 of the 279 studies in Alzheimer Disease with a site in Spain are open now. Recruiting first, the newest first:

49 more — sign in →

All 54 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 60 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 279 studies in Alzheimer Disease with a site in Spain, or all of them as a file.
02

Study summary

This study aims to evaluate whether immersive virtual reality (VR) can improve cognitive function and memory in patients with Alzheimer's disease. Twenty participants in Burgos, Spain, will engage in VR sessions that recreate scenes from 1960s Burgos, representing environments familiar from the participants' youth. The effects of these VR-based cognitive stimulation sessions will be assessed through pre- and post-intervention evaluations, including behavioral observations, EEG monitoring of brain activity, and standardized neurocognitive tests (Montreal Cognitive Assessment, Clock-Drawing Test, and Verbal Fluency Test).

Read the detailed description

Introduction: Alzheimer's disease is a neurodegenerative condition characterized by progressive cognitive decline. Virtual reality (VR) technologies offer an innovative approach to cognitive stimulation in patients with this condition. This study will evaluate the impact of VR on memory and cognition improvement in patients with Alzheimer's disease in Burgos.

Objective: Evaluate the effectiveness of cognitive and memory stimulation through virtual reality experiences in patients with Alzheimer's disease, using behavioral analysis, biometric data (EEG), and neurocognitive testing.

Methodology: A total of 20 patients diagnosed with Alzheimer's disease at a specialized center in Burgos will be selected. The patients will be exposed to virtual reality scenarios recreating the city of Burgos in the 1960s, a period corresponding to their youth. Their cognitive and emotional status will be assessed before and after the sessions using neurocognitive tests, behavioral monitoring, and biometric data recording (EEG). Analyses of variance (ANOVA), analyses of covariance (ANCOVA), and multivariate analyses of variance (MANOVA) were perfomed

03

Conditions studied

  • Alzheimer Disease
  • Memory Disorders

Keywords

  • alzheimer disease
  • virtual reality
  • cognitive therapy
  • neuropsychological tests
04

Who can participate

Ages eligible
60 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with mild cognitive impairment
  • Aged 60 years or older.
  • Resident or attending care at the Alzheimer's care center in Burgos.
  • Capable of providing , either directly or through a legally authorized representative.
  • Adequate vision and hearing (corrected if necessary) to engage with the VR experience.
  • Able to tolerate wearing a VR headset for sessions of approximately 15-30 minutes.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of other neurodegenerative disorders (e.g., Parkinson's disease, Huntington's disease, multiple sclerosis).
  • History of severe psychiatric disorders (e.g., schizophrenia, bipolar disorder).
  • Severe vision or hearing impairment that cannot be corrected (e.g., legal blindness).
  • History of epilepsy, seizure disorders, or other conditions that may be aggravated by VR exposure.
  • Active skin conditions or infections that prevent the use of a VR headset or EEG sensors.
  • Participation in another interventional clinical trial within the last 30 days.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Experimental group

    The sample consisted of 33 people: 16 in the experimental group.

    Other: Virtual reality

  • No intervention
    Control group

    The sample consisted of 33 people: 17 in the control group.

Interventions

  • OtherVirtual reality

    The intervention consists of a series of immersive virtual reality (VR) sessions designed to provide cognitive stimulation for patients diagnosed with Alzheimer's disease. Participants in the experimental group will be exposed to VR environments that recreate the city of Burgos as it appeared in the 1960s, an era corresponding to their youth. These VR experiences will include familiar scenes, landmarks, and culturally relevant settings designed to evoke personal memories and enhance cognitive engagement.

06

What researchers measure

Primary outcomes

  1. Change in Cognitive Function (Montreal Cognitive Assessment - MoCA)

    Change in cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA). The MoCA evaluates multiple cognitive domains, including memory, attention, language, executive function, and visuospatial abilities. Total scores range from 0 to 30, with higher scores indicating better cognitive function. The change score will be calculated as the post-intervention score minus the baseline score.

    Time frame: Baseline and immediately after the last virtual reality session

Secondary outcomes

  1. Change in emotional well-being assessed with the Satisfaction With Life Scale (SWLS)

    Change in emotional well-being will be assessed using the Satisfaction With Life Scale (SWLS). The SWLS is a 5-item scale that assesses global life satisfaction. Total scores range from 5 to 35, with higher scores indicating greater satisfaction with life and better emotional well-being. The change score will be calculated as the post-intervention score minus the baseline score.

    Time frame: Baseline and immediately after the last virtual reality session

  2. Change in Verbal Fluency (Verbal Fluency Test)

    Change in the number of words generated in a 60-second period, assessing language and cognitive processing speed.

    Time frame: Baseline and post-intervention.

  3. Change in attention and processing speed

    Attention, visual scanning, and processing speed will be assessed using the Trail Making Test Part A. The outcome will be the time required to complete the task. Lower completion times indicate better performance.

    Time frame: Baseline and immediately after the last virtual reality session

  4. Change in executive function and cognitive flexibility assessed with the Trail Making Test Part B (TMT-B)

    Executive function and cognitive flexibility will be assessed using the Trail Making Test Part B. The outcome will be the time required to complete the task. Lower completion times indicate better performance.

    Time frame: Baseline and immediately after the last virtual reality session

  5. Change in positive affect assessed with the Positive and Negative Affect Schedule Short Form (PANAS-S)

    Positive affect will be assessed using the positive affect subscale of the Positive and Negative Affect Schedule Short Form (PANAS-S). Higher scores indicate greater positive affect.

    Time frame: Baseline and immediately after the last virtual reality session.

  6. Change in negative affect assessed with the Positive and Negative Affect Schedule Short Form (PANAS-S)

    Negative affect will be assessed using the negative affect subscale of the Positive and Negative Affect Schedule Short Form (PANAS-S). Higher scores indicate greater negative affect.

    Time frame: Baseline and immediately after the last virtual reality session

  7. Immediate emotional response assessed with an Emotional Visual Analog Scale

    Immediate emotional response will be assessed after each intervention session using an Emotional Visual Analog Scale ranging from 0 to 10, where higher scores indicate a more positive emotional state.

    Time frame: Baseline and immediately after the last virtual reality session

07

Study locations

1 site
  • University of Burgos
    Burgos, Burgos 09001, Spain
08

References and documents

Publications

  • Redmond LW. Spiritual coping tools of religious victims of childhood sexual abuse. J Pastoral Care Counsel. 2014 Mar-Jun;68(1-2):3. PubMed 25241481 ↗
  • Maggio MG, Latella D, Maresca G, Sciarrone F, Manuli A, Naro A, De Luca R, Calabro RS. Virtual Reality and Cognitive Rehabilitation in People With Stroke: An Overview. J Neurosci Nurs. 2019 Apr;51(2):101-105. doi: 10.1097/JNN.0000000000000423. PubMed 30649091 ↗
  • Zhang J, Wu M, Li J, Song W, Lin X, Zhu L. Effects of virtual reality-based rehabilitation on cognitive function and mood in multiple sclerosis: A systematic review and meta-analysis of randomized controlled trials. Mult Scler Relat Disord. 2024 Jul;87:105643. doi: 10.1016/j.msard.2024.105643. Epub 2024 May 9. PubMed 38735202 ↗
  • Garcia-Betances RI, Jimenez-Mixco V, Arredondo MT, Cabrera-Umpierrez MF. Using virtual reality for cognitive training of the elderly. Am J Alzheimers Dis Other Demen. 2015 Feb;30(1):49-54. doi: 10.1177/1533317514545866. Epub 2014 Aug 7. PubMed 25107931 ↗
  • Wang Z, Cao Y, Zhang K, Guo Z, Liu Y, Zhou P, Liu Z, Lu X. Gold nanoparticles alleviates the lipopolysaccharide-induced intestinal epithelial barrier dysfunction. Bioengineered. 2021 Dec;12(1):6472-6483. doi: 10.1080/21655979.2021.1972782. PubMed 34523392 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Mar 2025, 2 months.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's 2 months is below that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2026
First posted
Jun 12, 2026
StartActual
Jan 8, 2025
Primary completionActual
Mar 20, 2025
CompletionActual
Mar 20, 2025
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07645638
Lead sponsor
Universidad de Burgos
Responsible party
Sponsor
First posted
Jun 12, 2026
Start date
Jan 8, 2025
Primary completion
Mar 20, 2025
Completion
Mar 20, 2025
Last update
Jun 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion